A Phase 3 interventional study of clopidogrel and clopidogrel plus placebo in Stable Angina Pectoris and Ad Hoc Percutaneous Coronary Intervention, sponsored by University of Pecs. Terminated at 1 site in Hungary. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-03-23.
Sponsored by University of Pecs · Phase 3, Interventional, and Treatment
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to 75 mg clopidogrel after elective percutaneous coronary intervention.
519 studies on the registry are indexed under Angina Pectoris; 82 are open to participants now.
This study's planned enrollment of 500 is above the median of 123 across 336 interventional studies indexed under Angina Pectoris.
Browse Angina Pectoris studies →University of Pecs is the lead sponsor of 100 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel
Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days
Drug: clopidogrel
Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel
Drug: clopidogrel plus placebo
150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
Cardiac death or non-fatal myocardial infarction or ischemia-driven target vessel revascularisation.
Time frame: 12 months
Academic Research Consortium (ARC) definite / probable stent thrombosis
Time frame: 12 months
Cardiac death and non-fatal myocardial infarction
Time frame: 12 months
Cardiac death or non-fatal myocardial infarction or ischemia-driven target vessel revascularisation or TIMI major/minor bleeding
Time frame: 12 months
5 microM ADP-induced platelet aggregation assessed by light transmission aggregometer
Time frame: 25 +/-2 days
VASP-PRI
Time frame: 25 +/-2 days
This study is terminated, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Pecs